Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01858896 · ClinicalTrials.gov registry record · Early Phase 1
GLP-1 and Hypoglycemia
A Early Phase 1 study of Type 2 Diabetes Mellitus, sponsored by University of Maryland, Baltimore.
- Active
- Registry status
- Early Phase 1
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT01858896: Active Early Phase 1 study of Type 2 Diabetes Mellitus, sponsored by University of Maryland, Baltimore.
NCT01858896 is a Early Phase 1 study of Type 2 Diabetes Mellitus that is active but no longer recruiting, run by University of Maryland, Baltimore. The registered enrollment target is 28 participants, below the 2,960-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01858896, a Early Phase 1 study of Type 2 Diabetes Mellitus, is active but no longer recruiting, sponsored by University of Maryland, Baltimore.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
Low blood sugar can negatively affect how blood vessels function, and this can lead to an increase in the risk for heart attacks, strokes and other problems related to the stiffening and blockage of blood vessels. The purpose of this study is to learn if and how glucagon-like peptide-1 (GLP-1; a naturally occurring hormone in the gut) changes the effects that low blood sugar levels have on blood vessels.
Primary Outcome
measurements of change in PAi-1 at baseline and during the end of the glucose clamp period (2 hours)
Conditions Studied
Interventions
- DRUG Glucagon-Like Peptide- 1 (GLP-1) infusion
- OTHER Placebo Comparator: Saline Infusion
Study Locations (1)
Maryland
- University of Maryland, Baltimore - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2013-07 |
| Est. Completion | 2026-12 |
| Phase | Early Phase 1 |
What the registry record for NCT01858896 still lists
NCT01858896 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 2,960-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Glucagon-Like Peptide- 1 (GLP-1) infusion is the first listed.
NCT01858896 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT01858896 about?
NCT01858896 is a clinical study titled "GLP-1 and Hypoglycemia". Low blood sugar can negatively affect how blood vessels function, and this can lead to an increase in the risk for heart attacks, strokes and other problems related to the stiffening and blockage of blood vessels. The purpose of this study is to learn if and how glucagon-like peptide-1 (GLP-1; a nat...
What is the current status of trial NCT01858896?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 28 participants. The study started on 2013-07. Estimated completion is 2026-12.
What conditions does trial NCT01858896 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT01858896?
The interventions under investigation include: Glucagon-Like Peptide- 1 (GLP-1) infusion (DRUG), Placebo Comparator: Saline Infusion (OTHER).
Who is sponsoring clinical trial NCT01858896?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01858896 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01858896's enrollment target sits among peer trials
28 96th of 130 higher than 35 of 130 other Type 2 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Determinants of Diabetes Remission After Gastric Bypass Surgery
COMPLETED · Early Phase 1
-
The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass
COMPLETED · Early Phase 1
-
The PRECISION II Study: Evaluating the Accuracy of the LabPatch Glucose Sensing System
RECRUITING
-
A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus
RECRUITING · Phase 1
-
An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
RECRUITING
-
Preventing Type 2 Diabetes in Black Emergent Adult
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia